Novo Nordisk A/S $NVO Shares Sold by Clear Street Group Inc.

Clear Street Group Inc. decreased its holdings in Novo Nordisk A/S (NYSE:NVO) by 42.8% during the 4th quarter, HoldingsChannel reports. The fund owned 580,826 shares of the company’s stock after selling 435,174 shares during the quarter. Clear Street Group Inc.’s holdings in Novo Nordisk A/S were worth $29,552,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Smith Chas P & Associates PA Cpas raised its stake in Novo Nordisk A/S by 105.3% during the third quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock valued at $22,497,000 after buying an additional 207,959 shares in the last quarter. Clifford Swan Investment Counsel LLC raised its stake in Novo Nordisk A/S by 13.7% during the third quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock valued at $17,267,000 after buying an additional 37,453 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Novo Nordisk A/S during the third quarter valued at approximately $3,171,000. Romano Brothers AND Company raised its stake in Novo Nordisk A/S by 704.0% during the fourth quarter. Romano Brothers AND Company now owns 34,236 shares of the company’s stock valued at $1,742,000 after buying an additional 29,978 shares in the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new stake in Novo Nordisk A/S during the third quarter valued at approximately $19,519,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on NVO. Deutsche Bank Aktiengesellschaft cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Sanford C. Bernstein began coverage on Novo Nordisk A/S in a research note on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price objective on the stock. Nordea Equity Research cut Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. Finally, Weiss Ratings cut Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Four analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $65.56.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: UK regulators approved Novo Nordisk’s daily Wegovy pill, making it the first GLP-1 weight-loss tablet approved in the UK. That expands the company’s obesity franchise beyond injections and could open a new growth channel. UK approves Novo weight-loss pill to edge open European market
• Positive Sentiment: Several follow-up reports highlighted the UK approval as a milestone that could help Novo regain momentum in the obesity market and broaden access to Wegovy through private prescriptions. Novo Nordisk Wegovy pill becomes first daily GLP-1 weight-loss pill approved in the UK
• Positive Sentiment: Analysts also raised FY2026 EPS estimates slightly, signaling still-solid earnings expectations despite recent share-price weakness. Novo Nordisk A/S Trading Down 0.1%
• Neutral Sentiment: Some commentary on the “Wegovy pill” said the approval is encouraging but not yet enough to make certain investors buy, suggesting the market may want more proof of commercial impact before re-rating the stock. Novo Nordisk: Wegovy Pill Is Encouraging But Still Not Enough To Make Me Buy
• Negative Sentiment: Novo Nordisk disclosed an IT security incident involving unauthorized access to internal systems and potential data copying, which could pressure investor confidence even though the company said operations were not materially affected. Novo Nordisk hit by cyber incident, probes data breach
• Negative Sentiment: Another report said some U.S. employers may drop GLP-1 obesity-drug coverage in 2027, a potential headwind for long-term demand and reimbursement for Wegovy and rival products. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $43.90 on Friday. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $81.44. The firm has a market capitalization of $196.02 billion, a price-to-earnings ratio of 10.31, a price-to-earnings-growth ratio of 3.92 and a beta of 0.78. The business has a 50 day simple moving average of $42.28 and a 200 day simple moving average of $46.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The business had revenue of $10.85 billion during the quarter. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.45 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.